Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00186589 | 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL | PHASE1 | COMPLETED | 30 | — | — | May 1, 2004 | Jul 1, 2007 | Jun 6, 2012 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| 90Y Ibritumomab tiuxetan | DRUG | - |
Inclusion Criteria:Inclusion Criteria -- Step 1 4.1 Histologically proven, recurrent or refractory, CD20+ B-cell NHL reviewed at SUMC. 4.11 The definition of recurrent disease is: previous partial response (PR) or complete response (CR) to treatment followed by disease progression. 4.12 The defin...